ARCUTIS BIOTHERAPEUTICS, INC. Revenue Not from Contract with Customer
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Revenue Not from Contract with Customer of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RevenueNotFromContractWithCustomer · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. revenue not from contract with customer for the quarter ending 2026-06-30 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. revenue not from contract with customer for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. revenue not from contract with customer for the quarter ending 2025-12-31 was $2.00M, a 0.00% change year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. revenue not from contract with customer for the quarter ending 2025-09-30 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. revenue not from contract with customer for fiscal 2025 was $4.00M, a 86.67% decline from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. revenue not from contract with customer for fiscal 2024 was $30.00M, a 1.38% decline from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. revenue not from contract with customer for fiscal 2023 was $30.42M.
- ARCUTIS BIOTHERAPEUTICS, INC. revenue not from contract with customer for fiscal 2022 was $0.00.
| Period end | Revenue Not from Contract with Customer 3 month | Revenue Not from Contract with Customer 6 month | Revenue Not from Contract with Customer 9 month | Revenue Not from Contract with Customer 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | $2.00M derived: sum of 3 quarters · filed 2026-08-05 | $2.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-06 | $2.00M derived: sum of 2 quarters · filed 2026-05-06 | $2.00M derived: sum of 3 quarters · filed 2026-05-06 | $2.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $2.00M derived: sum of 2 quarters · filed 2026-02-25 | $2.00M derived: sum of 3 quarters · filed 2026-08-05 | $4.00M 10-K · filed 2026-02-25 |
| 2025-09-30 | $0.00 10-Q · filed 2025-10-28 | $0.00 derived: sum of 2 quarters · filed 2026-08-05 | $2.00M 10-Q · filed 2025-10-28 | $4.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-05 | $2.00M 10-Q · filed 2026-08-05 | $4.00M derived: sum of 3 quarters · filed 2026-08-05 | $4.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $2.00M 10-Q · filed 2026-05-06 | $4.00M derived: sum of 2 quarters · filed 2026-05-06 | $4.00M derived: sum of 3 quarters · filed 2026-05-06 | $4.00M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $2.00M derived: sum of 2 quarters · filed 2026-02-25 | $2.00M derived: sum of 3 quarters · filed 2026-02-25 | $30.00M 10-K · filed 2026-02-25 |
| 2024-09-30 | $0.00 10-Q · filed 2025-10-28 | $0.00 derived: sum of 2 quarters · filed 2025-10-28 | $28.00M 10-Q · filed 2025-10-28 | $28.00M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-06 | $28.00M 10-Q · filed 2025-08-06 | $28.00M derived: sum of 3 quarters · filed 2026-02-25 | $58.00M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $28.00M 10-Q · filed 2025-05-06 | $28.00M derived: sum of 2 quarters · filed 2026-02-25 | $58.00M derived: sum of 3 quarters · filed 2026-02-25 | $58.42M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $30.00M derived: sum of 2 quarters · filed 2026-02-25 | $30.42M derived: sum of 3 quarters · filed 2026-02-25 | $30.42M 10-K · filed 2026-02-25 |
| 2023-09-30 | $30.00M 10-Q · filed 2024-11-06 | $30.42M derived: sum of 2 quarters · filed 2024-11-06 | $30.42M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $420.00K 10-Q · filed 2024-08-14 | $420.00K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-25 | |||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |